Cell Therapeutics Inc (NASDAQ:CTIC)
The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
pchop123
(76.57)
Submitted: 6/11/2013 3:31:05 PM :
Start Price:
$1.21
CTIC Score:
+2.72
Speculation to the UPside
Recs
Allstar13913
(99.78)
Submitted: 4/27/2013 10:11:59 PM :
Start Price:
$1.18
CTIC Score:
-2.30
Worthless Biopharm company. Has a drug twice rejected by the FDA but was approved for European use. AVOID.
Recs
bIlluminati
(31.13)
Submitted: 4/24/2013 12:02:32 PM :
Start Price:
$1.12
CTIC Score:
-7.50
No profits. Book less than price. Reverse splits as far as the eye can see. Last revenue in 2010. Spends $100 million per year. Only product is sale of new shares.
Recs
zzlangerhans
(99.74)
Submitted: 3/4/2013 8:01:15 PM :
Start Price:
$1.26
CTIC Score:
-9.12
My last green thumb on Cell Therapeutics worked out so well, I've decided to go for it again. Cell Therapeutics might not be the worst biopharma out there right now (hard to beat Pluristem, Star Scientific, and Cellceutix), but it is definitely the worst biopharma out there over the course of its existence.
Pixuvri is charting a predictably rocky course towards commercialization in the EU, with an apparent negative opinion on the cost efficacy coming from the German IQWiG committee last week. CEO Jim Bianco took time off his busy schedule of spa treatments to brush off the snub, and indeed a final decision has to be made by the higher bureaucratic authority G-BA before a final decision on reimbursement is made. I expect trouble from the UK's NICE as well.
Hopefully Cell Therapeutics can manufacture some positive catalysts from the rest of their wide but dubious pipeline prior to further mud being thrown at Pixuvri in Europe. Enrollment has begun in the PERSIST-1 phase III trial of pacritinib in myelofibrosis, and a second phase III trial is planned for H2 2013. Tosedostat also continues in phase II trials in AML/MDS. A predicted January interim analysis of a trial of Opaxio in ovarian cancer has failed to materialize. Knowing the history of Cell Therapeutics and Jim Bianco, it might be wise to start looking for an Opaxio-sized coffin.
Recs
aaronleetx
(< 20)
Submitted: 1/8/2013 5:18:56 PM :
Start Price:
$1.55
CTIC Score:
-32.09
I think you guys will be awsome!!!!:D
Recs
OBAMABB
(< 20)
Submitted: 6/26/2012 7:10:59 PM :
Start Price:
$2.95
CTIC Score:
-81.81
Keep Bashing CTIC 65 times in 6 months means you are trying to manipulate the stock your buddies must be real short!
Recs
bobleelaw
(35.39)
Submitted: 6/22/2012 7:02:32 PM :
Start Price:
$3.10
CTIC Score:
-84.21
Cell Therapeutics, Inc. (CTIC)
Is well undervalued for what it has in the pipeline. This stock will be 100+% investor return in the next 6 months. I am not sure why it is not getting the attention it should, but that is fine by me as I accumulate shares on the cheap.
Recs
liken22
(< 20)
Submitted: 1/30/2012 10:59:47 AM :
Start Price:
$5.41
CTIC Score:
-102.65
Hit the lowest cap in a long time, so I think will go up
Recs
tommywaaf
(< 20)
Submitted: 1/26/2012 5:14:28 PM :
Start Price:
$6.75
CTIC Score:
-106.78
Euro possible apporval in mid feb. Could bring interest
Recs
ltgenspecific
(< 20)
Submitted: 6/14/2010 5:44:12 PM :
Start Price:
$14.94
CTIC Score:
-119.26
going with the gut, something's bound to give, Pixuvri seems to be somewhat effective... risky but if it takes, it'll run
Recs
libertybrewcity
(< 20)
Submitted: 9/3/2009 12:59:57 AM :
Start Price:
$45.90
CTIC Score:
-161.85
The new drug is about to go into phase 3 and the stock will explode!
Recs
dbbfool63
(32.86)
Submitted: 8/27/2009 6:28:48 PM :
Start Price:
$47.70
CTIC Score:
-155.90
Good entry point for mid to long term.
I couldn't get in until it got above a dollar to rate it although been watching since .o7/shr.
Probably could of got in lower, but lost track watching others.
Recs
aikiboy2k
(52.13)
Submitted: 8/26/2009 1:23:37 PM :
Start Price:
$48.00
CTIC Score:
-158.01
New cancer drug looks like it will be accepted by FDA.
Recs
Brian7992
(48.36)
Submitted: 8/20/2009 7:40:30 AM :
Start Price:
$50.40
CTIC Score:
-162.58
Best Bio Bets
Recs
STERLINGACTERRA
(< 20)
Submitted: 8/6/2009 1:31:28 PM :
Start Price:
$45.90
CTIC Score:
-163.06
I HAVE BEEN FOLLOWING CTIC FOR ABOUT 6 MONTHS NOW...HAVE CASHED OUT ON PROFITS ONCE SO FAR AND WILL AGAIN VERY SOON. TOOK PART IN THE PHONE UPDATE THIS MORNING AND BOUGHT ANOTHER BLOCK OF STOCKS...I'M A STRONG BELIEVER THAT THIS STOCK WILL SOON TAKE OFF.
FDA WILL DECIDE ABOUT FAST TRACK LATER THIS MONTH...SHOULD SEE A JUMP IN STOCK STRENGTH IN THE WEEK LEADING UP TO THE ANNOUNCEMENT THEN ANOTHER JUMP IF CTIC RECEIVES A FAVORABLE DECISSION. DECEMBER 24TH WILL THEN BRING A VERY HAPPY HOLIDAY TO THE SHAREHOLDERS. LET IT BE WRITTEN ...LET IT BE DONE!
Recs
janineboulayseib
(30.59)
Submitted: 8/5/2009 9:22:40 AM :
Start Price:
$46.80
CTIC Score:
-162.74
Pussing several promissing drugs to market, plenty of cash on hand, look at the price, cant go anywhere but up......
Recs
garrick1
(< 20)
Submitted: 7/5/2009 5:05:55 PM :
Start Price:
$45.00
CTIC Score:
-183.00
3 major new cancer fighting drugs just had successful trials and should roll out over the next few months, conservatively doubling the stock price by year's end.
Recs
LinuxCentOS
(32.00)
Submitted: 6/30/2009 6:23:35 PM :
Start Price:
$51.60
CTIC Score:
-176.43
Drugs in pipeline.
Recs
mjspillman
(< 20)
Submitted: 6/25/2009 3:13:43 PM :
Start Price:
$46.50
CTIC Score:
-177.36
Their products are unique and effective within the biotech industry.
Recs
stockcousin
(< 20)
Submitted: 6/25/2009 2:33:52 PM :
Start Price:
$45.90
CTIC Score:
-177.91
I believe that Cell Therapeutic's new drug, Pixantrone will help this company go over the top. They've recently submitted it to the FDA and if it goes thru, the stock prices could really climb.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 47 : 1 2 3 Next »